| A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes |
|
Clin Lymphoma Myeloma Leuk |
Myelodysplastic Syndromes (MDS) |
| Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. |
|
Cancer Med |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Rethinking clinical trial endpoints in myelodysplastic syndromes. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. |
|
Bone Marrow Transplant |
Myelodysplastic Syndromes (MDS) |
| Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. |
|
Leuk Lymphoma. |
Myelodysplastic Syndromes (MDS) |
| Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
|
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
| TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. |
|
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
| Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. |
|
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
